We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure (STANDUP AHF)

This study is currently recruiting participants.
Verified December 2017 by Bristol-Myers Squibb
Sponsor:
ClinicalTrials.gov Identifier:
NCT03016325
First Posted: January 10, 2017
Last Update Posted: December 7, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Bristol-Myers Squibb
  Purpose
A Study to Evaluate Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of HNO Donor in Hospitalized Patients with Heart Failure and Impaired Systolic Function

Condition Intervention Phase
Heart Failure Drug: HNO Donor Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospitalized Patients With Heart Failure and Impaired Systolic Function

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Clinically relevant hypotension [ Time Frame: Hour 0 to 6 hours after the end of study drug infusion ]

Secondary Outcome Measures:
  • Change in NT-proBNP (N-terminal prohormone of brain natriuretic peptide) [ Time Frame: From baseline to hour 24, 48, 72, 120 or discharge (whichever comes first), and at day 32 ]
  • Change in patient-reported resting dyspnea, as measured by the area under the curve (AUC) of the 11-point Numerical Rating Scale (NRS) [ Time Frame: From baseline to hour 6, 12, 24, 48 and 72 ]

Estimated Enrollment: 310
Actual Study Start Date: January 6, 2017
Estimated Study Completion Date: October 2, 2019
Estimated Primary Completion Date: May 4, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part 1 Cohort 1 HNO Donor Drug: HNO Donor
Infusion
Other Name: BMS-986231
Placebo Comparator: Placebo Part 1 Cohort 1 Drug: Placebo
Infusion
Experimental: Part 2 Cohort 2 HNO Donor- low dose Drug: HNO Donor
Infusion
Other Name: BMS-986231
Experimental: Part 2 Cohort 2 HNO Donor- high dose Drug: HNO Donor
Infusion
Other Name: BMS-986231
Placebo Comparator: Placebo Part 2 Cohort 2 Drug: Placebo
Infusion

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Actively being hospitalized for acute decompensated heart failure
  • At least 1 administration of IV diuretic for the current episode
  • Be randomized within 18 hours of first dose of IV diuretic for current episode
  • Have shortness of breath at rest or with minimal exertion after administration of 1 dose of IV diuretic
  • Have history of heart failure and a left ventricular ejection fraction (LVEF) ≤ 40%

Exclusion Criteria:

  • Systolic blood pressure <105mm Hg or >160mm Hg or heart rate <50 or >130 bpm
  • Have an active infection requiring IV anti-microbial treatment
  • Severe lung disease that may interfere with assessments (e.g., severe chronic obstructive pulmonary disease, active asthma or acute pneumonia)
  • Be hospitalized with acute coronary syndrome, coronary revascularization or acute myocardial infarction during the previous 90 days prior to screening
  • Have a history of a cerebral vascular accident (CVA or stroke) or of a transient ischemic attack (TIA) during the previous 90 days prior to screening

Other protocol defined inclusion/exclusion criteria could apply

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03016325


Contacts
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email: Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT# and Site #.

  Show 117 Study Locations
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT03016325     History of Changes
Other Study ID Numbers: CV013-011
2016-001685-29 ( EudraCT Number )
First Submitted: January 9, 2017
First Posted: January 10, 2017
Last Update Posted: December 7, 2017
Last Verified: December 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases